Changing the Standard of Care for Patients with RET Fusion+ Metastatic NSCLCJoin OncLive® and Blueprint Medicines for a Live Broadcast on the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.© 2020 Blueprint Medicines Corporation. 08/2020 USBP-DA-20-010.1Register for 5:00 PM…
Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.
A series of events took John L. Marshall, MD, down his path of becoming a gastrointestinal oncology leader, with a drive that has also solidified…
Felipe Batalini, MD, and Alberto Montero, MD, MBA, CPHQ, detail how allosteric inhibitors targeting PIK3CA such as STX-478 may reduce toxicities seen with orthosteric inhibitors.
Experts across the fields of lung and GI cancer share key information and insights from 2 recent OncLive biomarker consortiums.
IO-202 plus azacitidine elicited an ORR of 66.7% in patients with HMA-naive chronic myelomonocytic leukemia.
Navtemadlin monotherapy was safe and effective among patients with myelofibrosis who were relapsed or refractory to treatment with JAK inhibitors.
Pembrolizumab plus chemotherapy conferred an efficacy advantage over chemotherapy alone in high-risk TNBC subgroups defined by potential biomarkers.
The GPRC5D-targeting CAR T-cell therapy arlocabtagene autoleucel also yielded a 53% complete response rate in relapsed/refractory multiple myeloma.
Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.
Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2…
